Pharmacological characterization of a 5-HT receptor in locust nervous tissue.
A 5-HT receptor in the nervous tissue of the desert locust (Schistocerca gregaria Forsk.) was investigated, using [3H]LSD (lysergic acid diethylamide) as the radioligand. [3H]LSD labels in addition a putative dopamine receptor whose specific [3H]LSD binding nevertheless could easily be diminished by co-incubation with 1 microM dopamine. The binding site was characterized by a KD of 1.64 nM, and a maximal concentration of binding sites of 79.8 fmol/mg protein. Pharmacological investigation revealed a relatively low affinity for the putative natural agonist, serotonin (KI = 0.209 microM). In contrast to the high affinity of classical serotonergic antagonists (e.g. dihydroergotamine or (+)-butaclamol) substances with subtype specificity such as 8-OH-DPAT (8-hydroxyl-1-(N,N-dipropyl)-aminotetralin) or ketanserin have only moderate affinities. Quantitative comparison of the pharmacological data demonstrated that there is obviously no pharmacological homology with vertebrate 5-HT receptors characterized so far. The only receptors with a close pharmacological relationship to the 5-HT receptor of locusts are the 5-HTdro1 receptor expressed in Drosophila nervous tissue and a 5-HT receptor in snail nervous tissue which might be homologous to that of locusts. The 5-HT receptor investigated, was shown to be G-protein-coupled, as addition of stable GTP analogues or depletion of Mg2+ ions from the incubation medium led to agonist-specific lowering of the affinity.
Wedemeyer
S
S
Universität Hamburg, Zoologisches Institut, Neurophysiologie, Hamburg, Germany.
Roeder
T
T
Gewecke
M
M
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology; D001665:Binding Sites; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D004298:Dopamine / Q000494:pharmacology; D004947:Esophagus / Q000187:drug effects; D005260:Female; D019204:GTP-Binding Proteins / Q000378:metabolism; D006110:Grasshoppers / Q000378:metabolism*; D007650:Ketanserin / Q000494:pharmacology; D008238:Lysergic Acid Diethylamide / Q000378:metabolism*; D008274:Magnesium / Q000378:metabolism; D008297:Male; D011954:Receptors, Dopamine / Q000378:metabolism; D011985:Receptors, Serotonin / Q000378:metabolism*; D012701:Serotonin / Q000494:pharmacology; D012702:Serotonin Antagonists / Q000494:pharmacology; D017366:Serotonin Receptor Agonists / Q000494:pharmacology; D013900:Thoracic Nerves / Q000187:drug effects
D014150:Antipsychotic Agents; D011954:Receptors, Dopamine; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; D012701:Serotonin; D008238:Lysergic Acid Diethylamide; D007650:Ketanserin; D019204:GTP-Binding Proteins; D008274:Magnesium; D004298:Dopamine